Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Oak Harvest Investment Services

Oak Harvest Investment Services boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,277 shares of the biopharmaceutical company’s stock after purchasing an additional 66 shares during the period. Oak Harvest Investment Services’ holdings in Regeneron Pharmaceuticals were worth $1,229,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $932,571,000. International Assets Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after purchasing an additional 590,314 shares in the last quarter. Global Assets Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $339,594,000. First Trust Advisors LP grew its stake in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares in the last quarter. Finally, abrdn plc raised its holdings in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,208 shares of company stock valued at $62,514,142. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $20.57 during mid-day trading on Thursday, reaching $1,024.09. 378,341 shares of the stock were exchanged, compared to its average volume of 459,242. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $688.52 and a 1 year high of $1,081.17. The company has a 50 day simple moving average of $992.50 and a 200-day simple moving average of $954.60. The stock has a market capitalization of $112.84 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.16 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Truist Financial restated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.